Dixon Hubard Feinour & Brown’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $6.17M | Sell |
19,034
-664
| -3% | -$199K | 0.73% | 48 |
|
|
2022
Q1 | $5.64M | Sell |
19,698
-85
| -0.4% | -$21.9K | 0.56% | 49 |
|
|
2021
Q4 | $5.46M | Sell |
19,783
-9
| -0% | -$2.28K | 0.53% | 58 |
|
|
2021
Q3 | $4.57M | Sell |
19,792
-1,212
| -6% | -$299K | 0.97% | 32 |
|
|
2021
Q2 | $4.82M | Sell |
21,004
-24,952
| -54% | -$5.01M | 1% | 30 |
|
|
2021
Q1 | $7.64M | Buy |
45,956
+21,594
| +89% | +$4.22M | 0.94% | 28 |
|
|
2020
Q4 | $3.61M | Hold |
24,362
| – | – | 0.92% | 29 |
|
|
2020
Q3 | $3.61M | Sell |
24,362
-1,175
| -5% | -$182K | 0.92% | 29 |
|
|
2020
Q2 | $4.15M | Sell |
25,537
-680
| -3% | -$104K | 1.08% | 28 |
|
|
2020
Q1 | $3.64M | Sell |
26,217
-483
| -2% | -$66.4K | 1.23% | 28 |
|
|
2019
Q4 | $3.51M | Sell |
26,700
-97
| -0.4% | -$11.2K | 0.91% | 37 |
|
|
2019
Q3 | $3M | Sell |
26,797
-191
| -0.7% | -$21.3K | 0.83% | 35 |
|
|
2019
Q2 | $2.99M | Buy |
26,988
+473
| +2% | +$55.7K | 0.85% | 33 |
|
|
2019
Q1 | $3.44M | Buy |
26,515
+480
| +2% | +$58.4K | 1.04% | 31 |
|
|
2018
Q4 | $3.01M | Hold |
26,035
| – | – | 1.12% | 29 |
|
|
2018
Q3 | $2.79M | Buy |
26,035
+200
| +0.8% | +$20K | 0.77% | 37 |
|
|
2018
Q2 | $2.21M | Sell |
25,835
-760
| -3% | -$62.4K | 0.64% | 48 |
|
|
2018
Q1 | $2.06M | Sell |
26,595
-695
| -3% | -$56K | 0.57% | 51 |
|
|
2017
Q4 | $2.31M | Sell |
27,290
-250
| -0.9% | -$21.3K | 0.62% | 47 |
|
|
2017
Q3 | $2.36M | Sell |
27,540
-1,050
| -4% | -$86.1K | 0.68% | 46 |
|
|
2017
Q2 | $2.35M | Sell |
28,590
-600
| -2% | -$49K | 0.68% | 46 |
|
|
2017
Q1 | $2.46M | Sell |
29,190
-100
| -0.3% | -$8.01K | 0.73% | 42 |
|
|
2016
Q4 | $2.15M | Sell |
29,290
-1,145
| -4% | -$85.3K | 0.68% | 45 |
|
|
2016
Q3 | $2.44M | Sell |
30,435
-1,775
| -6% | -$142K | 0.76% | 40 |
|
|
2016
Q2 | $2.54M | Buy |
32,210
+150
| +0.5% | +$11.3K | 0.81% | 38 |
|
|
2016
Q1 | $2.42M | Sell |
32,060
-3,625
| -10% | -$274K | 0.79% | 40 |
|
|
2015
Q4 | $3.01M | Sell |
35,685
-498
| -1% | -$41.3K | 0.96% | 34 |
|
|
2015
Q3 | $3.03M | Sell |
36,183
-700
| -2% | -$59.1K | 1.12% | 31 |
|
|
2015
Q2 | $3.08M | Sell |
36,883
-1,115
| -3% | -$85K | 0.95% | 36 |
|
|
2015
Q1 | $2.76M | Buy |
37,998
+600
| +2% | +$42.7K | 0.82% | 41 |
|
|
2014
Q4 | $2.58M | Sell |
37,398
-484
| -1% | -$32.7K | 0.8% | 40 |
|
|
2014
Q3 | $2.46M | Buy |
37,882
+9,460
| +33% | +$599K | 0.81% | 41 |
|
|
2014
Q2 | $1.77M | Buy |
28,422
+2,150
| +8% | +$128K | 0.58% | 50 |
|
|
2014
Q1 | $1.55M | Sell |
26,272
-1,270
| -5% | -$70.9K | 0.54% | 53 |
|
|
2013
Q4 | $1.41M | Sell |
27,542
-1,550
| -5% | -$77.6K | 0.52% | 55 |
|
|
2013
Q3 | $1.46M | Sell |
29,092
-405
| -1% | -$21.2K | 0.62% | 50 |
|
|
2013
Q2 | $1.45M | Buy |
+29,497
| New | +$1.6M | 0.65% | 48 |
|
Other funds holding LLY
Dixon Hubard Feinour & Brown's LLY Position: Q2 2022 in Review
Dixon Hubard Feinour & Brown reduced its Eli Lilly (LLY) stake by 3.4% in Q2 2022, selling an estimated $199K and leaving 19,034 shares worth $6.17M. The position accounts for 0.73% of the portfolio, ranked #48.
Dixon Hubard Feinour & Brown first reported a position in LLY in Q2 2013 and has held it in 37 quarters since. The position peaked at $7.64M in Q1 2021. 2,445 funds tracked by Wall St. Rank hold LLY as of Q2 2022.
- Dixon Hubard Feinour & Brown held 19,034 shares of Eli Lilly worth $6.17M as of Q2 2022.
- Dixon Hubard Feinour & Brown sold 664 Eli Lilly shares in Q2 2022, an estimated $199K.
- Eli Lilly made up 0.73% of Dixon Hubard Feinour & Brown's portfolio in Q2 2022, its #48 holding.
- Dixon Hubard Feinour & Brown first reported a position in Eli Lilly in Q2 2013 and has held it in 37 quarters since.
- Dixon Hubard Feinour & Brown's Eli Lilly position peaked at $7.64M in Q1 2021.
- 2,445 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2022.
Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2022, filed 22 Jul 2022.